119 related articles for article (PubMed ID: 4066708)
1. Specific chemical modifications in the beta-cleft site of hemoglobin. Potential anti-sickling agents with hybrid functionalities.
Klotz IM; Haney DN; Wood LE
J Biol Chem; 1985 Dec; 260(30):16215-23. PubMed ID: 4066708
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
[TBL] [Abstract][Full Text] [Related]
3. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
Pagare PP; Ghatge MS; Musayev FN; Deshpande TM; Chen Q; Braxton C; Kim S; Venitz J; Zhang Y; Abdulmalik O; Safo MK
Bioorg Med Chem; 2018 May; 26(9):2530-2538. PubMed ID: 29655608
[TBL] [Abstract][Full Text] [Related]
4. Structural specificities in acylation of hemoglobin and sickle hemoglobin by diaspirins.
Wood LE; Haney DN; Patel JR; Clare SE; Shi GY; King LC; Klotz IM
J Biol Chem; 1981 Jul; 256(13):7046-52. PubMed ID: 7240262
[TBL] [Abstract][Full Text] [Related]
5. Structural features required for the reactivity and intracellular transport of bis(3,5-dibromosalicyl)fumarate and related anti-sickling compounds that modify hemoglobin S at the 2,3-diphosphoglycerate binding site.
Chatterjee R; Iwai Y; Walder RY; Walder JA
J Biol Chem; 1984 Dec; 259(23):14863-73. PubMed ID: 6501320
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ
J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.
Omar AM; Mahran MA; Ghatge MS; Chowdhury N; Bamane FH; El-Araby ME; Abdulmalik O; Safo MK
Org Biomol Chem; 2015 Jun; 13(22):6353-70. PubMed ID: 25974708
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis for the anti-sickling activity of aromatic amino acids and related compounds: a proton nuclear magnetic resonance investigation.
Russu IM; Lin AK; Yang CP; Ho C
Biochemistry; 1986 Feb; 25(4):808-15. PubMed ID: 3964645
[TBL] [Abstract][Full Text] [Related]
9. Physiological and x-ray studies of potential antisickling agents.
Abraham DJ; Perutz MF; Phillips SE
Proc Natl Acad Sci U S A; 1983 Jan; 80(2):324-8. PubMed ID: 6572894
[TBL] [Abstract][Full Text] [Related]
10. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.
Omar AM; Abdulmalik O; El-Say KM; Ghatge MS; Cyril-Olutayo M; Paredes S; Al-Awadh M; El-Araby ME; Safo MK
Chem Biol Drug Des; 2024 Jan; 103(1):e14371. PubMed ID: 37798397
[TBL] [Abstract][Full Text] [Related]
11. Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.
Deshpande TM; Pagare PP; Ghatge MS; Chen Q; Musayev FN; Venitz J; Zhang Y; Abdulmalik O; Safo MK
Acta Crystallogr D Struct Biol; 2018 Oct; 74(Pt 10):956-964. PubMed ID: 30289405
[TBL] [Abstract][Full Text] [Related]
12. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.
Abdulmalik O; Ghatge MS; Musayev FN; Parikh A; Chen Q; Yang J; Nnamani I; Danso-Danquah R; Eseonu DN; Asakura T; Abraham DJ; Venitz J; Safo MK
Acta Crystallogr D Biol Crystallogr; 2011 Nov; 67(Pt 11):920-8. PubMed ID: 22101818
[TBL] [Abstract][Full Text] [Related]
13. Chemical modification of human hemoglobin by antisickling concentrations of nitrogen mustard.
Roth EF; Arnone A; Bookchin RM; Nagel RL
Blood; 1981 Aug; 58(2):300-8. PubMed ID: 7248523
[No Abstract] [Full Text] [Related]
14. Design, synthesis, and testing of potential antisickling agents. 9. Cyclic tetrapeptide homologs as mimics of the mutation site of hemoglobin S.
Sheh L; Mokotoff M; Abraham DJ
Int J Pept Protein Res; 1987 Apr; 29(4):509-20. PubMed ID: 3596902
[TBL] [Abstract][Full Text] [Related]
15. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
Oder E; Safo MK; Abdulmalik O; Kato GJ
Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
Fatope MO; Abraham DJ
J Med Chem; 1987 Nov; 30(11):1973-7. PubMed ID: 3669005
[TBL] [Abstract][Full Text] [Related]
17. Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.
Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Singer M; Russell MO; Schwartz E
Proc Natl Acad Sci U S A; 1980 May; 77(5):2955-9. PubMed ID: 6930678
[TBL] [Abstract][Full Text] [Related]
18. Thermodynamics of anti-sickling agents with hemoglobin S.
Benedict RC; Richey B; Fall L; Gill SJ; Nagel RL; Wyman J
J Mol Biol; 1981 Aug; 150(3):423-34. PubMed ID: 7299823
[No Abstract] [Full Text] [Related]
19. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde.
Manning JM; Acharya AS
Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764
[TBL] [Abstract][Full Text] [Related]
20. Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.
Omar AM; Mahran MA; Ghatge MS; Bamane FH; Ahmed MH; El-Araby ME; Abdulmalik O; Safo MK
Molecules; 2016 Aug; 21(8):. PubMed ID: 27529207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
